Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 15, 2021, titled "Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu��) in 1000+ COVID‐19 patients, findings reinforce the drug s safety and efficacy in real world settings".